Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Phase 2 Completed 21 enrolled Duke University National Cancer Institute (NCI) · collab Novartis Pharmaceuticals · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as hydroxyurea, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving imatinib mesylate together with hydroxyurea may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving imatinib mesylate together with hydroxyurea works in treating patients with recurrent or progressive meningioma.

Timeline

Start: 2005-05
Primary completion: 2009-03
Completion: 2010-10

Publications

Results Reardon DA, Norden AD, Desjardins A, Vredenburgh JJ, Herndon JE 2nd, Coan A, Sampson JH, Gururangan S, Peters KB, McLendon RE, Norfleet JA, Lipp ES, Drappatz J, Wen PY, Friedman HS. Phase II study of Gleevec(R) plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012 Jan;106(2):409-15. doi: 10.1007/s11060-011-0687-1. Epub 2011 Sep 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Hydroxyurea	Other / unclassified	500 mg	Oral
Subject	Imatinib	Small molecule	400 mg	Oral
Subject	Imatinib	Small molecule	500 mg	Oral

Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma

Summary

Timeline

Publications

Drugs

Indications